Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Biogen Inc.

(BGEN)

Matthew Geller of Oppenheimer & Co. raised his rating on the Cambridge, Mass., company to "buy" and added it to Oppenheimer's "recommended" list. Geller said that BGEN's beta interferon

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE